Published in
Wiley, British Journal of Haematology, 3(182), p. 429-433
DOI: 10.1111/bjh.14793
Links
Tools
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
Journal article published in 2017 by
Guy Pratt 
,
Christina Yap,
Ceri Oldreive,
Daniel Slade,
Rebecca Bishop,
Mike Griffiths,
Martin J. S. Dyer,
Chris Fegan ,
David Oscier,
Andrew Pettitt,
Estella Matutes,
Stephen Devereux,
David Allsup,
Adrian Bloor,
Peter Hillmen
and other authors.
,
Christina Yap,
Ceri Oldreive,
Daniel Slade,
Rebecca Bishop,
Mike Griffiths,
Martin J. S. Dyer,
Chris Fegan ,
David Oscier,
Andrew Pettitt,
Estella Matutes,
Stephen Devereux,
David Allsup,
Adrian Bloor,
Peter Hillmen
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
